Skip to main content
SpringerLink
Log in

Locally Advanced Breast Cancer (LABC)

  • Chapter
  • First Online:
Surgical Oncology

Abstract

Locally advanced breast (LABC) consists of inflammatory breast cancer (IBC) and non-IBC locally advanced breast cancer (non-IBC LABC).Although the diagnostic work-ups and management are similar, there are subtle differences in terms of biology and surgical management. Some of the topics in this chapter overlapped those in the early breast cancer chapter, Chap. 4. Therefore, readers are encouraged to review the early breast cancer chapter in order to have a more comprehensive understanding of managing patients with LABC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Shulman LN, Willett W, Sievers A, Knaul FM. Breast cancer in developing countries: opportunities for improved survival. J Oncol. 2010;2010:595167.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20(17): 3628–36.

    Article  PubMed  Google Scholar 

  3. Walshe JM, Swain SM. Clinical aspects of inflammatory breast cancer. Breast Dis. 2005;22: 35–44.

    PubMed  Google Scholar 

  4. Dawood S, Ueno NT, Valero V, et al. Incidence of and survival following brain metastases among women with inflammatory breast cancer. Ann Oncol. 2010;21(12):2348–55.

    Article  PubMed  CAS  Google Scholar 

  5. Bonnier P, Charpin C, Lejeune C, et al. Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition? Int J Cancer. 1995;62(4):382–5.

    Article  PubMed  CAS  Google Scholar 

  6. Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011;22(3):515–23.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  7. Anderson WF, Chu KC, Chang S. Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol. 2003;21(12):2254–9.

    Article  PubMed  Google Scholar 

  8. Dawood S, Ueno NT, Valero V, et al. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer. 2011;117(9):1819–26.

    Article  PubMed  Google Scholar 

  9. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am. 1995;4(4):715–34.

    PubMed  CAS  Google Scholar 

  10. Paradiso A, Tommasi S, Brandi M, et al. Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer. 1989;64(9):1922–7.

    Article  PubMed  CAS  Google Scholar 

  11. Parton M, Dowsett M, Ashley S, Hills M, Lowe F, Smith IE. High incidence of HER-2 positivity in inflammatory breast cancer. Breast. 2004;13(2): 97–103.

    Article  PubMed  CAS  Google Scholar 

  12. Charafe-Jauffret E, Tarpin C, Bardou VJ, et al. Immunophenotypic analysis of inflammatory breast cancers: identification of an “inflammatory signature”. J Pathol. 2004;202(3):265–73.

    Article  PubMed  Google Scholar 

  13. Colpaert CG, Vermeulen PB, Benoy I, et al. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer. 2003;88(5): 718–25.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Cristofanilli M, Valero V, Buzdar AU, et al. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer. 2007;110(7):1436–44.

    Article  PubMed  Google Scholar 

  15. Li BD, Sicard MA, Ampil F, et al. Trimodal therapy for inflammatory breast cancer: a surgeon’s perspective. Oncology. 2010;79(1–2):3–12.

    Article  PubMed  Google Scholar 

  16. Yang WT, Le-Petross HT, Macapinlac H, et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat. 2008;109(3):417–26.

    Article  PubMed  CAS  Google Scholar 

  17. Renz DM, Baltzer PA, Böttcher J, et al. Inflammatory breast carcinoma in magnetic resonance imaging: a comparison with locally advanced breast cancer. Acad Radiol. 2008;15(2):209–21.

    Article  PubMed  Google Scholar 

  18. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–95.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48–72.

    PubMed  CAS  Google Scholar 

  20. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.

    Article  PubMed  Google Scholar 

  21. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241–56.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Chu QD, Henderson A, Kim RH, et al. Should a routine metastatic workup be performed for all patients with pathologic N2/N3 breast cancer? J Am Coll Surg. 2012;214(4):456–61; discussion 461–452.

    Article  PubMed  Google Scholar 

  23. National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (2013). Accessed 23 May 2013.

  24. Groheux D, Giacchetti S, Delord M, et al. 18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging. J Nucl Med. 2013;54(1):5–11.

    Article  PubMed  Google Scholar 

  25. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.

    Article  PubMed  Google Scholar 

  26. Perez CA, Fields JN, Fracasso PM, et al. Management of locally advanced carcinoma of the breast. II Inflammatory carcinoma. Cancer. 1994;74 Suppl 1:466–76.

    Article  PubMed  CAS  Google Scholar 

  27. Giordano SH. Update on locally advanced breast cancer. Oncologist. 2003;8(6):521–30.

    Article  PubMed  Google Scholar 

  28. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712): 377–84.

    Article  PubMed  CAS  Google Scholar 

  29. Thoms WW, McNeese MD, Fletcher GH, Buzdar AU, Singletary SE, Oswald MJ. Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 1989;17(4):739–45.

    Article  PubMed  Google Scholar 

  30. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7):2483–93.

    PubMed  CAS  Google Scholar 

  31. Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, et al. Meta-analysis results from the Collaborative Trials in Neoadjuvant Breast Cancer. 2012 San Antonio Breast Cancer Symposium. Cancer Res. 2012;72(24 (Suppl 3)):Abstract S1–11.

    Google Scholar 

  32. Dawood S, Gonzalez-Angulo AM, Peintinger F, et al. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D Anderson experience. Cancer. 2007;110(6):1195–200.

    Article  PubMed  CAS  Google Scholar 

  33. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–804.

    Article  Google Scholar 

  34. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24(12):1940–9.

    Article  PubMed  Google Scholar 

  35. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17(2):460–9.

    PubMed  CAS  Google Scholar 

  36. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, et al. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer. 2006;106(5):1000–6.

    Article  PubMed  Google Scholar 

  37. Dowsett M, Smith IE, Ebbs SR, et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res. 2005;11(2 Pt 2):951s–8s.

    PubMed  CAS  Google Scholar 

  38. Petit T, Wilt M, Velten M, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 2004;40(2):205–11.

    Article  PubMed  CAS  Google Scholar 

  39. McGuire SE, Gonzalez-Angulo AM, Huang EH, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007;68(4):1004–9.

    Article  PubMed  Google Scholar 

  40. Le Scodan R, Selz J, Stevens D, et al. Radiotherapy for stage II and stage III breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys. 2012;82(1):e1–7.

    Article  PubMed  Google Scholar 

  41. Buchholz TA, Lehman CD, Harris JR, et al. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol. 2008;26(5):791–7.

    Article  PubMed  Google Scholar 

  42. Sinclair S, Swain SM. Primary systemic chemotherapy for inflammatory breast cancer. Cancer. 2010; 116 Suppl 11:2821–8.

    Article  PubMed  CAS  Google Scholar 

  43. Mamounas EP. Neoadjuvant chemotherapy for operable breast cancer: is this the future? Clin Breast Cancer. 2003;4 Suppl 1:S10–9.

    Article  PubMed  Google Scholar 

  44. Liu SV, Melstrom L, Yao K, Russell CA, Sener SF. Neoadjuvant therapy for breast cancer. J Surg Oncol. 2010;101(4):283–91.

    Article  PubMed  CAS  Google Scholar 

  45. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(3): 188–94.

    Article  PubMed  Google Scholar 

  46. Cunningham JD, Weiss SE, Ahmed S, et al. The efficacy of neoadjuvant chemotherapy compared to postoperative therapy in the treatment of locally advanced breast cancer. Cancer Invest. 1998;16(2):80–6.

    Article  PubMed  CAS  Google Scholar 

  47. Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D Anderson Cancer Center. Cancer Chemother Pharmacol. 1997;40(4):321–9.

    Article  PubMed  CAS  Google Scholar 

  48. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21(22):4165–74.

    Article  PubMed  CAS  Google Scholar 

  49. von Minckwitz G, Kümmel S, Vogel P, et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst. 2008;100(8): 552–62.

    Article  CAS  Google Scholar 

  50. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;20(6):1456–66.

    Article  PubMed  CAS  Google Scholar 

  51. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, Kau SW, Frye DK, Hortobagyi GN. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D Anderson Cancer Center experience. Clin Breast Cancer. 2004;4(6):415–9.

    Article  PubMed  CAS  Google Scholar 

  52. Charehbili A, Fontein DB, Kroep JR, et al. Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: a systematic review. Cancer Treat Rev. 2014;40(1):86–92.

    Article  PubMed  CAS  Google Scholar 

  53. clinicaltrials.gov/show/NCT01622361. Neo-adjuvant study of chemotherapy versus endocrine therapy in premenopausal patient with hormone responsive, HER2 negative, lymph node positive breast cancer (NEST). 2013. Accessed 12 Feb 2014.

    Google Scholar 

  54. Dixon JM, Anderson TJ, Miller WR. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur J Cancer. 2002;38(17):2214–21.

    Article  PubMed  CAS  Google Scholar 

  55. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19(18):3808–16.

    PubMed  CAS  Google Scholar 

  56. Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the pre-operative “Arimidex” compared to Tamoxifen (PROACT) trial. Cancer. 2006;106(10):2095–103.

    Article  PubMed  CAS  Google Scholar 

  57. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001;12(11):1527–32.

    Article  PubMed  CAS  Google Scholar 

  58. Masuda N, Sagara Y, Kinoshita T, et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol. 2012;13(4):345–52.

    Article  PubMed  CAS  Google Scholar 

  59. Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype – ACOSOG Z103. J Clin Oncol. 2011;29(17):2342–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  60. Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23(22):5108–16.

    Article  PubMed  CAS  Google Scholar 

  61. Cardoso F, Loibl S, Pagani O, et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer. 2012;48(18):3355–77.

    Article  PubMed  Google Scholar 

  62. Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008;100(19):1380–8.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  63. Hind D, Wyld L, Beverley CB, Reed MW. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev. 2006;(1), CD004272.

    Google Scholar 

  64. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, et al. Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT + H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer. J Clin Oncol. 2013;31(Suppl):Abstract 503.

    Google Scholar 

  65. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.

    Article  PubMed  CAS  Google Scholar 

  66. Boussen H, Cristofanilli M, Zaks T, DeSilvio M, Salazar V, Spector N. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J Clin Oncol. 2010;28(20):3248–55.

    Article  PubMed  CAS  Google Scholar 

  67. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278–84.

    Article  PubMed  CAS  Google Scholar 

  68. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.

    Article  PubMed  CAS  Google Scholar 

  69. Guarneri V, Frassoldati A, Bottini A, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol. 2012;30(16):1989–95.

    Article  PubMed  CAS  Google Scholar 

  70. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379(9816): 633–40.

    Article  PubMed  CAS  Google Scholar 

  71. Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012;13(2):135–44.

    Article  PubMed  CAS  Google Scholar 

  72. Robidoux A, Tang G, Rastogi P, et al. Evaluation of lapatinib as a component of neoadjuvant therapy for HER-2+ operable breast cancer: NSABP protocol B-41. J Clin Oncol. 2012;30(18 (Suppl)):Abstract LBA506.

    Google Scholar 

  73. von Minckwitz G, Eidtmann H, Loibl S, et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol. 2011;22(2):301–6.

    Article  Google Scholar 

  74. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24(5):769–77.

    Article  PubMed  CAS  Google Scholar 

  75. Greil R, Moik M, Reitsamer R, et al. Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: efficacy and safety in a phase II pilot study. Eur J Surg Oncol. 2009;35(10):1048–54.

    Article  PubMed  CAS  Google Scholar 

  76. Yardley D, Raefsky E, Castillo R, Lahiry A, LoCicero D, et al. Results of a multicenter pilot study of weekly nab-paclitaxel, carboplatin with bevacizumab, and trastuzumab as neoadjuvant therapy in HER2+ locally advanced breast cancer with SPARC correlatives. J Clin Oncol. 2009;27(15s (Suppl)):Abstract 527.

    Google Scholar 

  77. Hurvitz S, Bosserman L, Leland-Jones B, Thirwell M, Allison M, et al. A multicenter, double-blind randomized phase II trial of neoadjuvant treatment with single-agent bevacizumab or placebo, followed by docetaxel, doxorubicin, and cyclophosphamide (TAC), with or without bevacizumab, in patients with stage II or stage III breast cancer. J Clin Oncol. 2008;26(15S (Suppl)):Abstract 562.

    Google Scholar 

  78. Overmoyer B, Silverman P, Leeming R, Shenk R, et al. Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer. J Clin Oncol. 2004;22(14S (Suppl)):Abstract 727.

    Google Scholar 

  79. Waintraub S, Tuchman V. The role of preoperative neoadjuvant cytoreductive dose-dense bevacizumab plus docetaxel followed by bevacizumab-doxorubicin-cyclophosphamide regimen in locally advanced operable breast cancer. J Clin Oncol. 2009;27(15S (Suppl)):Abstract e11524.

    Google Scholar 

  80. Hylton NM, Blume JD, Bernreuter WK, et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy–results from ACRIN 6657/I-SPY TRIAL. Radiology. 2012;263(3):663–72.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Prevos R, Smidt ML, Tjan-Heijnen VC, et al. Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review. Eur Radiol. 2012;22(12):2607–16.

    Article  PubMed  CAS  Google Scholar 

  82. von Minckwitz G, Kümmel S, Vogel P, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst. 2008;100(8): 542–51.

    Article  CAS  Google Scholar 

  83. McGuire KP, Toro-Burguete J, Dang H, et al. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol. 2011;18(11):3149–54.

    Article  PubMed  Google Scholar 

  84. Loo CE, Straver ME, Rodenhuis S, et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol. 2011;29(6): 660–6.

    Article  PubMed  Google Scholar 

  85. Chen JH, Mehta RS, Nalcioglu O, Su MY. Inflammatory breast cancer after neoadjuvant chemotherapy: can magnetic resonance imaging precisely diagnose the final pathological response? Ann Surg Oncol. 2008;15(12):3609–13.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Avril N, Sassen S, Roylance R. Response to therapy in breast cancer. J Nucl Med. 2009;50 Suppl 1: 55S–63.

    Article  PubMed  CAS  Google Scholar 

  87. Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy. Cancer. 2005;103(4):689–95.

    Article  PubMed  Google Scholar 

  88. Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–61.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  89. Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609–18.

    Article  PubMed  Google Scholar 

  90. Kaufmann M, von Minckwitz G, Mamounas EP, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19(5):1508–16.

    Article  PubMed  Google Scholar 

  91. Edeiken BS, Fornage BD, Bedi DG, et al. US-guided implantation of metallic markers for permanent localization of the tumor bed in patients with breast cancer who undergo preoperative chemotherapy. Radiology. 1999;213(3):895–900.

    Article  PubMed  CAS  Google Scholar 

  92. Dash N, Chafin SH, Johnson RR, Contractor FM. Usefulness of tissue marker clips in patients undergoing neoadjuvant chemotherapy for breast cancer. AJR Am J Roentgenol. 1999;173(4):911–7.

    Article  PubMed  CAS  Google Scholar 

  93. Fleming RY, Asmar L, Buzdar AU, et al. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol. 1997;4(6):452–61.

    Article  PubMed  CAS  Google Scholar 

  94. Chu QD, McDonald JC, Li BD. Adjuvant therapy for patients who have node-positive breast cancer. Adv Surg. 2006;40:77–98.

    Article  PubMed  Google Scholar 

  95. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337(14):956–62.

    Article  PubMed  CAS  Google Scholar 

  96. Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97(2):116–26.

    Article  PubMed  Google Scholar 

  97. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337(14):949–55.

    Article  PubMed  CAS  Google Scholar 

  98. Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999; 353(9165):1641–8.

    Article  PubMed  CAS  Google Scholar 

  99. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. Early Breast Cancer Trialists’ Collaborative Group. N Engl J Med. 1995;333(22):1444–55.

    Google Scholar 

  100. Cuzick J, Stewart H, Peto R, et al. Overview of randomized trials comparing radical mastectomy without radiotherapy against simple mastectomy with radiotherapy in breast cancer. Cancer Treat Rep. 1987;71(1):7–14.

    PubMed  CAS  Google Scholar 

  101. Cuzick J, Stewart H, Rutqvist L, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol. 1994;12(3):447–53.

    PubMed  CAS  Google Scholar 

  102. Whelan TJ, Julian J, Wright J, Jadad AR, Levine ML. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol. 2000;18(6):1220–9.

    PubMed  CAS  Google Scholar 

  103. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet. 2000;355(9217):1757–70.

    Google Scholar 

  104. Taghian A, Jeong JH, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004;22(21):4247–54.

    Article  PubMed  Google Scholar 

  105. Recht A, Gray R, Davidson NE, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol. 1999;17(6):1689–700.

    PubMed  CAS  Google Scholar 

  106. Katz A, Strom EA, Buchholz TA, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol. 2000;18(15): 2817–27.

    PubMed  CAS  Google Scholar 

  107. Wallgren A, Bonetti M, Gelber RD, et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol. 2003;21(7):1205–13.

    Article  PubMed  CAS  Google Scholar 

  108. Pierce LJ. The use of radiotherapy after mastectomy: a review of the literature. J Clin Oncol. 2005;23(8): 1706–17.

    Article  PubMed  Google Scholar 

  109. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.

    Article  PubMed  CAS  Google Scholar 

  110. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Kyndi M, Sørensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26(9):1419–26.

    Article  PubMed  CAS  Google Scholar 

  112. Somlo G, Frankel P, Chow W, et al. Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol. 2004;22(10):1839–48.

    Article  PubMed  Google Scholar 

  113. Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 1988;62(12):2507–16.

    Article  PubMed  CAS  Google Scholar 

  114. Perloff M, Lesnick GJ, Korzun A, et al. Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study. J Clin Oncol. 1988;6(2):261–9.

    PubMed  CAS  Google Scholar 

  115. Pierce LJ, Lippman M, Ben-Baruch N, et al. The effect of systemic therapy on local-regional control in locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 1992;23(5):949–60.

    Article  PubMed  CAS  Google Scholar 

  116. Low JA, Berman AW, Steinberg SM, Danforth DN, Lippman ME, Swain SM. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol. 2004;22(20):4067–74.

    Article  PubMed  CAS  Google Scholar 

  117. Colozza M, Gori S, Mosconi AM, et al. Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long-term results. Am J Clin Oncol. 1996;19(1):10–7.

    Article  PubMed  CAS  Google Scholar 

  118. Clark J, Rosenman J, Cance W, Halle J, Graham M. Extending the indications for breast-conserving treatment to patients with locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 1998;42(2): 345–50.

    Article  PubMed  CAS  Google Scholar 

  119. Cristofanilli M, Buzdar AU, Sneige N, et al. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001;92(7):1775–82.

    Article  PubMed  CAS  Google Scholar 

  120. Favret AM, Carlson RW, Goffinet DR, Jeffrey SS, Dirbas FM, Stockdale FE. Locally advanced breast cancer: is surgery necessary? Breast J. 2001;7(2): 131–7.

    Article  PubMed  CAS  Google Scholar 

  121. Hutcheon AW, Heys SD, Sarkar TK, Group AB. Neoadjuvant docetaxel in locally advanced breast cancer. Breast Cancer Res Treat. 2003;79 Suppl 1:S19–24.

    Article  PubMed  CAS  Google Scholar 

  122. Harris EE, Schultz D, Bertsch H, Fox K, Glick J, Solin LJ. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2003;55(5):1200–8.

    Article  PubMed  Google Scholar 

  123. McIntosh SA, Ogston KN, Payne S, et al. Local recurrence in patients with large and locally advanced breast cancer treated with primary chemotherapy. Am J Surg. 2003;185(6):525–31.

    Article  PubMed  Google Scholar 

  124. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol. 2003;21(5):843–50.

    Article  PubMed  CAS  Google Scholar 

  125. Espinosa E, Morales S, Borrega P, et al. Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer. Cancer Chemother Pharmacol. 2004;54(6):546–52.

    Article  PubMed  CAS  Google Scholar 

  126. Ezzat AA, Ibrahim EM, Ajarim DS, et al. Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients. Br J Cancer. 2004;90(5):968–74.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  127. Gajdos C, Tartter PI, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol. 2002;80(1):4–11.

    Article  PubMed  Google Scholar 

  128. Lebowitz PF, Eng-Wong J, Swain SM, et al. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res. 2004;10(20):6764–9.

    Article  PubMed  CAS  Google Scholar 

  129. de Matteis A, Nuzzo F, D’Aiuto G, et al. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study. Cancer. 2002;94(4):895–901.

    Article  PubMed  CAS  Google Scholar 

  130. Shen J, Valero V, Buchholz TA, et al. Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol. 2004;11(9): 854–60.

    Article  PubMed  Google Scholar 

  131. Thomas E, Holmes FA, Smith TL, et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol. 2004;22(12): 2294–302.

    Article  PubMed  CAS  Google Scholar 

  132. Erol K, Baltali E, Altundag K, et al. Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5-fluorouracil in locally advanced breast cancer. Onkologie. 2005;28(2):81–5.

    Article  PubMed  CAS  Google Scholar 

  133. Gradishar WJ, Wedam SB, Jahanzeb M, et al. Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann Oncol. 2005;16(8): 1297–304.

    Article  PubMed  CAS  Google Scholar 

  134. Kao J, Conzen SD, Jaskowiak NT, et al. Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials. Int J Radiat Oncol Biol Phys. 2005;61(4):1045–53.

    Article  PubMed  CAS  Google Scholar 

  135. Tham YL, Gomez LF, Mohsin S, et al. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat. 2005;94(3): 279–84.

    Article  PubMed  CAS  Google Scholar 

  136. Veyret C, Levy C, Chollet P, et al. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial. Cancer. 2006;107(11):2535–44.

    Article  PubMed  CAS  Google Scholar 

  137. Ellis G, Green S, Russell C, et al. SWOG 0012, a randomized phase III comparison of standard doxorubicin and cyclophosphamide followed by weekly paclitaxel versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24, LBA537.

    Article  Google Scholar 

  138. Villman K, Ohd JF, Lidbrink E, et al. A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer. Eur J Cancer. 2007; 43(7):1153–60.

    Article  PubMed  CAS  Google Scholar 

  139. Manga GP, Shahi PK, Ureña MM, et al. Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer. Breast Cancer. 2010;17(3):205–11.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Louisiana State University Health Sciences Center – Shreveport, 1501 Kings Highway, 33932, Shreveport, LA, 71130-3392, USA

    Quyen D. Chu M.D., M.B.A., FACS

  2. Department of Surgery, University of Ghana Medical School, Accra-North, AN-11835, 1233, Accra, Ghana

    Ernest Kwame Adjepong-Tandoh M.Bch.B.

  3. Department of Surgery, Beth Israel Deaconess Medical Center, Howard Medical School, 330 Brookline Ave. Stoneman 9- Surgical Oncology, Boston, MA, 02215, USA

    Rosemary Bernadette Duda M.D., MPH

Authors
  1. Quyen D. Chu M.D., M.B.A., FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ernest Kwame Adjepong-Tandoh M.Bch.B.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rosemary Bernadette Duda M.D., MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Quyen D. Chu M.D., M.B.A., FACS .

Editor information

Editors and Affiliations

  1. Department of Surgery, LSU Health Sciences Center-Shreveport, Shreveport, Louisiana, USA

    Quyen D. Chu

  2. Department of Surgery, Jersey Shore University Medical Center, Neptune, New Jersey, USA

    John F. Gibbs

  3. John C. McDonald Regional Transplant Center, Willis Knighton Health System, Shreveport, Louisiana, USA

    Gazi B. Zibari

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Chu, Q.D., Adjepong-Tandoh, E.K., Duda, R.B. (2015). Locally Advanced Breast Cancer (LABC). In: Chu, Q., Gibbs, J., Zibari, G. (eds) Surgical Oncology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1423-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1423-4_5

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1422-7

  • Online ISBN: 978-1-4939-1423-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation